Werewolf Therapeutics (NASDAQ:HOWL) Director Sells 76,928 Shares

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 76,928 shares of the stock in a transaction on Tuesday, June 9th. The stock was sold at an average price of $0.37, for a total value of $28,463.36. Following the completion of the sale, the director directly owned 300,283 shares in the company, valued at $111,104.71. This represents a 20.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Luke Evnin also recently made the following trade(s):

• On Monday, June 8th, Luke Evnin sold 60,547 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.40, for a total transaction of $24,218.80.
• On Friday, June 5th, Luke Evnin sold 24,946 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.40, for a total transaction of $9,978.40.
• On Thursday, June 4th, Luke Evnin sold 20,072 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.44, for a total transaction of $8,831.68.
• On Wednesday, June 3rd, Luke Evnin sold 29,749 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.42, for a total transaction of $12,494.58.
• On Tuesday, June 2nd, Luke Evnin sold 29,595 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.45, for a total transaction of $13,317.75.
• On Monday, June 1st, Luke Evnin sold 80,459 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.47, for a total transaction of $37,815.73.
• On Friday, May 29th, Luke Evnin sold 32,556 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.45, for a total transaction of $14,650.20.
• On Thursday, May 28th, Luke Evnin sold 27,698 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.46, for a total transaction of $12,741.08.
• On Wednesday, May 27th, Luke Evnin sold 80,852 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.48, for a total value of $38,808.96.
• On Tuesday, May 26th, Luke Evnin sold 67,950 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.47, for a total value of $31,936.50.

Werewolf Therapeutics Trading Down 2.5%

HOWL traded down $0.01 during trading hours on Wednesday, hitting $0.37. The company’s stock had a trading volume of 169,732 shares, compared to its average volume of 466,070. The company has a 50-day simple moving average of $0.69 and a 200 day simple moving average of $0.72. The firm has a market capitalization of $17.74 million, a PE ratio of -0.29 and a beta of 0.29. Werewolf Therapeutics, Inc. has a fifty-two week low of $0.36 and a fifty-two week high of $2.38.

Werewolf Therapeutics (NASDAQ:HOWL) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.04. Research analysts expect that Werewolf Therapeutics, Inc. will post -1.08 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Werewolf Therapeutics

A number of institutional investors have recently added to or reduced their stakes in HOWL. Regal Investment Advisors LLC lifted its position in Werewolf Therapeutics by 93.3% in the fourth quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock worth $33,000 after purchasing an additional 25,389 shares during the period. Vontobel Holding Ltd. lifted its position in Werewolf Therapeutics by 66.7% in the fourth quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock worth $38,000 after purchasing an additional 24,003 shares during the period. Qube Research & Technologies Ltd bought a new stake in Werewolf Therapeutics in the second quarter worth about $48,000. AQR Capital Management LLC acquired a new stake in Werewolf Therapeutics in the 1st quarter valued at about $79,000. Finally, Bridgeway Capital Management LLC lifted its holdings in Werewolf Therapeutics by 157.7% in the 2nd quarter. Bridgeway Capital Management LLC now owns 102,000 shares of the company’s stock valued at $111,000 after acquiring an additional 62,414 shares during the last quarter. 64.84% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have commented on HOWL shares. Wall Street Zen cut shares of Werewolf Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Werewolf Therapeutics in a research note on Monday, April 20th. Two equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Werewolf Therapeutics presently has a consensus rating of “Hold” and an average price target of $3.75.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.